



Improving Lives, Offering Hope

New Therapies for Cardiovascular & Neurological Diseases

Corporate Presentation
July/August 2020

James Bonnar – CEO
Prof. Gary Housley – Chair, Scientific Advisory Board

ASX:NYR



Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Nyrada Summary

Drug discoverer and early stage developer

Diverse product portfolio, significant therapeutic and commercial potential, near term milestones.

Cholesterol lowering (PCSK9 inhibitors) program to help up to 70% of patients taking statin drugs, a market worth approximately US\$19 billion.

Brain injury neuroprotectant program to help the more than 2.8 million people in the US who sustain a brain injury and 800,000 who suffer a stroke.


High calibre Board and Scientific Advisory Board, including highly connected industry and research experts in the US, Europe, Japan and Australia.

Well-funded to move programs into the clinic having raised \$8.5M at IPO, with \$5.1M cash in bank.

Commercial business model focused on maximising the value of early stage product candidates.



Business Model & Strategy



Cardiovascular



- 💊 Cholesterol-lowering treatment
- 💊 Value inflection point within 3 years
- 💊 US\$19B market

Neurology




- 💊 Brain injury treatment (stroke & head trauma)
- 💊 Value inflection points at 3 and 5 years
- 💊 US\$20B market

Cholesterol and Cardiovascular Disease

1 in 4 Deaths attributed to Cardiovascular Disease

- Tobacco use
- High blood pressure
- **High LDL cholesterol**



Cholesterol Problem (US)

62.6 million

Total US adults with
elevated LDL-C

19.4 million

Unable to achieve
LDL-C target despite
taking statin therapy

27.4 million

US adults with elevated
LDL-C are taking a statin

Current Treatment Options



Low cost generic statins available
US\$16 for 100 pills



Suboptimal efficacy
Side effects



Effective, combined with statin



Expensive US\$5,800 per year
Inconvenient

US\$900M global PCSK9 Inhibitor market in 2019

US\$19B global cholesterol-lowering drugs market in 2017 (CAGR 4.9%)¹

¹ Visiongain Market Research - Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs.


Nyrada Cholesterol-Lowering Solution

Nyrada
inc

NYX-PCSK9i binds to PCSK9

Blocks action of PCSK9
on cholesterol receptor

High PCSK9 =
high LDL cholesterol



Small molecule PCSK9 inhibitor
overcomes longstanding challenge
of an oral PCSK9 treatment

What is Unique?

Single pill
treatment

Convenient
for patient

Cost-
effective



NYX-PCSK9i Compared to Repatha[®] and Praluent[®]

- Nyrada NYX-PCSK9i shows equivalency to Repatha[®] and Praluent[®] in human white blood cells
- Confirmed with/without a statin, supporting NYX-PCSK9i use alone or in combination with statin

- Mevastatin

+ Mevastatin

% LDLR retention

p-value

% LDLR retention

p-value

No drug	51%	n/a	64%	n/a
NYX-PCSK9i (1 μM)	53%	0.74	78%	0.13
NYX-PCSK9i (2 μM)	64%	0.01	77%	0.06
→ NYX-PCSK9i (4 μM)	89%	0.001	90%	0.003
alirocumab (Praluent [®])	78%	0.002	88%	0.04
evolocumab (Repatha [®])	84%	0.0009	89%	0.0001

Brain Injury Problem


Each year in the US:

- 2.8 million people sustain a traumatic brain injury (TBI)
- 800,000 suffer a stroke

Neurology / physical rehabilitation only existing therapies


- One drug class for stroke (Suitable for less than 15% of patients)
- No treatment exists for TBI

- High mortality
- Severe life-long disability
- High ongoing healthcare cost




Minutes

Initial injury size



Hours



Days


Final injury size

Nyrada Brain Injury Solution



Treatment for secondary brain injury following Stroke or TBI

- Prevent cell death
- Attenuate damaged brain volume
- Improve survivability, limit disability, improve quality of life



Brain Injury Drug Market (US)

Hospital admissions each year / patients who present <12hr

**Traumatic
Brain Injury**
(Moderate / Severe)

210,000

Stroke

490,000

700,000
patients



Annual US market size for
brain injury combined
(approx.)

US\$20B global severe TBI treatment market in 2024 (CAGR 5%)¹

¹ Energias Market Research, Global Traumatic Brain Injuries Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

Preclinical Pharmacokinetic Rat Study

- Lead drug candidates maintained at therapeutic levels in the brain in PK rat study (intravenous dosing)
- Demonstrates delivery via preferred route for patients suffering from stroke and moderate-severe TBI with desired PK profiles for clinical studies



Program Status

Proof-of-concept
established



Lead optimisation well
advanced



First-in-human studies
(Phase I)

- Cholesterol-lowering Drug:
late-2021
- Brain Injury Drug:
mid-2022



Board of Directors



Mr John Moore
Non-Executive
Chairman



Dr Graham Kelly
Non-Executive
Director



Christopher Cox
Non- Executive
Director



Mr Peter Marks
Non- Executive
Director



Mr Marcus Frampton
Non- Executive
Director



Dr Rüdiger Weseloh
Non- Executive
Director

- 📌 **Nyrada operates under the direction of a board of international calibre**
- 📌 **Track record in founding and realising the value of biotech companies**

Key Metrics & News Flow

Market capitalisation
(as at 22 July 2020) **\$21M**

Share price
(as at 22 July 2020) **\$0.19**

CDIs free float **76,072,869**


CDIs 12 months escrow **205,000**


CDIs 24 months escrow **33,105,853**


Cash at bank (30 June 2020) **A\$5.1M**


ASX listing **January 16, 2020**

H2 2020	H1 2021	H2 2021	H1 2022
------------	------------	------------	------------

Clinical candidate selection for
cholesterol program: 

Clinical candidate selection for
neuroprotectant program: 

Cholesterol-lowering program
to enter clinic: 

Neuroprotection program
to enter clinic: 



Further preclinical results: **ongoing**

Potential industry collaborations / non-dilutive funding: **ongoing**


Discover More & Follow Us



Neuroprotection
Animation



Cholesterol-Lowering
Animation



Recent PCSK9i
Publication



@nyrada_inc



@nyrada_inc

www.nyrada.com